All News
GLP-1 drugs cost-effective for knee osteoarthritis and obesity
A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.
Read ArticleSARD-ILD: Significant diagnostic and treatment delays
Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? I have been asking myself that question after the recent publication of American Thoracic Society Interstitial Lung Disease screening guidelines. The ATS guidelines, which were published in May, recommend universal CT chest screening for all asymptomatic patients with RA, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren’s disease.
Read Article




Dr. John Cush RheumNow ( View Tweet)




Dr. John Cush RheumNow ( View Tweet)



Dr. John Cush RheumNow ( View Tweet)



Links:
Aurelie Najm AurelieRheumo ( View Tweet)

Links:

